Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community

31Citations
Citations of this article
103Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background Alcohol use disorders (AUDs) are highly prevalent among persons living with HIV (PLH) within the criminal justice system (CJS). Extended-release naltrexone (XR-NTX) has not been previously evaluated among CJS-involved PLH with AUDs. Methods A randomized, double-blind, placebo-controlled trial was conducted among 100 HIV+ prisoners with AUDs. Participants were randomized 2:1 to receive 6 monthly injections of XR-NTX or placebo starting one week prior to release. Using multiple imputation strategies for data missing completely at random, data were analyzed for the 6-month post-incarceration period. Main outcomes included: time to first heavy drinking day; number of standardized drinks/drinking day; percent of heavy drinking days; pre- to post-incarceration change in average drinks/day; total number of drinking days; and a composite alcohol improvement score comprised of all 5 parameters. Results There was no statistically significant difference overall between treatment arms for time-to-heavy-drinking day. However, participants aged 20–29 years who received XR-NTX had a longer time to first heavy drinking day compared to the placebo group (24.1 vs. 9.5 days; p < 0.001). There were no statistically significant differences between groups for other individual drinking outcomes. A sub-analysis, however, found participants who received ≥4 XR-NTX were more likely (p < 0.005) to have improved composite alcohol scores than the placebo group. Post-hoc power analysis revealed that despite the study being powered for HIV outcomes, sufficient power (0.94) was available to distinguish the observed differences. Conclusions Among CJS-involved PLH with AUDs transitioning to the community, XR-NTX lengthens the time to heavy drinking day for younger persons; reduces alcohol consumption when using a composite alcohol consumption score; and is not associated with any serious adverse events.

Cite

CITATION STYLE

APA

Springer, S. A., Di Paola, A., Azar, M. M., Barbour, R., Krishnan, A., & Altice, F. L. (2017). Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug and Alcohol Dependence, 174, 158–170. https://doi.org/10.1016/j.drugalcdep.2017.01.026

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free